Bad Medicine: Why India Is Racing To Improve Pharma Standards Amid US-China Trade Rivalry | Insight

Подробнее о видео

With the Biosecure Act passed by the US Congress, the US-China rivalry war has moved into pharmaceuticals. Citing national security concerns, American pharma companies could be limited from partnering their Chinese counterparts. China accounts for about 6% of drugs and 17% of raw material imports.

Enter India. As the third largest pharmaceutical manufacturing country, India can capitalise on the gap left by China. However, a spate of failed inspections and drug recalls have tarnished the reputation of India's drugmakers. So, earlier this year, the Modi government gave manufacturers one year to comply with a new set of standards.

What is behind the spotty quality controls in India's pharmaceutical sector? Can they raise standards to meet export requirements? And if they do not, what happens to patients?

00:00 Introduction
01:29 India pharma raising standards
04:39 Behind the US-China rivalry in biotech
08:19 Failed inspections and recalls of India-made drugs
12:09 How contaminated cough syrup led to child deaths
16:43 Poor regulation and cost cutting in manufacturing
23:39 Long-term health problems from bad medicine
24:36 Talcum powder found in antibiotics
27:05 Shortage of drug inspectors and testing facilities
29:07 Bad medicine in the domestic market
35:05 Are US and China headed for a biotech decoupling?
39:01 Why India lags behind China on biotech
44:16 The road ahead for India pharma

=========
ABOUT THE SHOW: Insight investigates and analyses topical issues that impact Asia and the rest of the world.
==================
#CNAInsider #CNAInsight #India #Pharma #US #China #Medical #Medicine #Biotech

For more, SUBSCRIBE to CNA INSIDER!


Follow CNA INSIDER on:
Instagram:
Facebook:
Website: